Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients.

What Was Tested

The paper reports a study of Losartan and Enalapril, published as a randomized controlled trial.

This study evaluates the uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia.

Who Took Part

According to the abstract, 10 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The patients were allocated by chance, so the Losartan group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Losartan.

Each person switched between Losartan and the comparison at some point, usually with a gap in between.

Office blood pressure, plasma uric acid levels, and urinary uric acid excretion were monitored throughout the study.

What Was Measured

This study evaluates the uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia.

The subject headings attached to it are Angiotensin Receptor Antagonists, Enalapril, Heart Transplantation, Losartan, Uric Acid and Uricosuric Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Losartan and Enalapril in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Transplantation), a journal based in United States.

More context: all human trials.